Casopitant
From Wikipedia, the free encyclopedia
Casopitant
|
|
Systematic (IUPAC) name | |
(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C30H35F7N4O2 |
Mol. mass | 616.26 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Casopitant (INN) is an neurokinin 1 receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is developed by GlaxoSmithKline and is likely to be marketed in the US as Rezonic and in the EU as Zunrisa.
[edit] References
- ^ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J 14 (2): 85–93. doi: . PMID 18391612.
|